MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jfma.2017.11.012

Медицинская библиотека · Journal of the Formosan Medical Association = Taiwan yi zhi · 2017

Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B.

Tseng Cheng-Hao, Hsu Yao-Chun, Chang Chi-Yang, Tseng Tai-Chung, Wu Ming-Shiang, Lin Jaw-Town, Kao Jia-Horng

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND/PURPOSE: The predictors of off-therapy response in patients treated with neucleos(t)ide analogue (NA) have not been elucidated. It remained unexplored whether serum level of hepatitis B core antibody (anti-HBc) at the end of NA therapy was associated with relapse risks.

METHODS

This prospective study monitored 82 chronic hepatitis B (CHB) patients after discontinuing entecavir. All patients had been treated for 3 years or longer and serologically negative for viral DNA and HBeAg at treatment cessation. Patients were monitored for virological relapse (viral DNA > 2000 IU/mL), and clinical relapse (serum alanine aminotransferase > 80 U/L plus virological relapse). The association between anti-HBc levels and the risk of relapse was assessed by the Cox analysis.

RESULTS

Clinical and virological relapses occurred in 29 and 60 participants, respectively, with the cumulative incidences of 23.7% (95% CI, 15.8-34.6%) and 62.0% (95% CI, 51.5-72.5%) at 1 year, and 36.2% (95% CI, 26.2-48.4%) and 78.8% (95% CI, 68.2-87.8%) at 2 years, respectively. There was a trend for an inverse association between anti-HBc and clinical relapse (crude hazard ratio [HR], 0.50; 95% CI, 0.24-1.05). All 3 patients with the level <100 IU/mL had a rapid clinical relapse (P = 0.002). This trend remained after adjustment for HBsAg and age (adjusted HR 0.50, 95% CI, 0.24-1.03). On the other hand, anti-HBc quantity was unrelated to virological relapse (crude HR, 0.97; 95% CI, 0.58-1.62; adjusted HR, 0.97; 95% CI, 0.58-1.60).

CONCLUSION

This pilot study suggests a trend for an inverse association between anti-HBc levels and clinical relapse in CHB patients off entecavir.

Для цитирования: Tseng Cheng-Hao, Hsu Yao-Chun, Chang Chi-Yang, Tseng Tai-Chung, Wu Ming-Shiang, Lin Jaw-Town, Kao Jia-Horng. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B.. Journal of the Formosan Medical Association = Taiwan yi zhi. 2017. DOI: 10.1016/j.jfma.2017.11.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.